Home Featured Page 139

Featured

Latest

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

PT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring...

Delix Therapeutics Expands World-Class Team with First Head of R&D

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health...

1...138139140...299 Page 139 of 299

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

PT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring...

Delix Therapeutics Expands World-Class Team with First Head of R&D

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health...

EDITOR PICKS

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY